Summary:
- LIR Life Sciences, a biopharmaceutical company, has filed a provisional patent application for a needle-free delivery system for GLP-GIP based obesity therapies.
- This novel delivery method could provide a more convenient and patient-friendly option for administering obesity treatments, as it eliminates the need for traditional needle injections.
- The GLP-GIP combination therapy targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which play key roles in regulating blood sugar levels and promoting weight loss.